Added to YB: 2026-01-12
Pitch date: 2026-01-01
GSK [neutral]
GSK plc
+2.68%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 75.7B
Pitch Price
GBP 18.28
Price Target
N/A
Dividend
3.23%
EV/EBITDA
9.22
P/E
14.19
EV/Sales
2.79
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | End of Year Review 2025 - GSK plc
GSK (holding update): +36% in 2025 on R&D pipeline momentum. 62 medicines/vaccines in development, 16 in Phase III. 15 scale opportunities with >£2bn peak sales potential launching 2025-31. £2bn buybacks, £1.7bn M&A spend. Upgraded 2025 guidance: 6-7% revenue growth, 10-12% core EPS growth. Trading 9.3x PE, 3.9% yield - momentum undervalued.
Read full article (1 min)